The core goal of precision medicine is to provide the right treatment to the right patients at the right time. The achievement of this goal relies on comprehensive analysis of massive multi-source data - from genome sequencing data, proteomics data, medical imaging, to electronic health records and wearable device data. Traditional statistical methods are struggling to handle such complex and heterogeneous data, while the rise of multimodal AI technology is fundamentally changing this situation.
━━
1、 Genomic analysis: from whole genome sequencing to clinical interpretation
The cost of whole genome sequencing (WGS) has decreased from $2.7 billion in 2003 to less than $500 by 2025, making large-scale genomic data collection possible. However, the human genome contains approximately 3 billion base pairs, and identifying disease-related variations from them has always been a major challenge in computational biology.
Deep learning models have made breakthrough progress in this field. Google DeepMind's AlphaFold series achieves atomic level accuracy in protein structure prediction, but its true value in the medical field lies in linking structure prediction with functional prediction. The latest AI models can directly predict protein functional changes based on genomic variations, and then evaluate their pathogenic potential. For example, the PrimateAI-3D genome interpretation model based on Transformer architecture can improve the pathogenicity classification accuracy of rare variants to over 88%, significantly better than traditional computational prediction methods.
2、 Multimodal Fusion: Unified Analysis of Imaging, Pathological, and Genetic Data
Another key application of multimodal AI is in precision diagnosis and treatment of tumors. Traditional cancer diagnosis relies on imaging (CT/MRI/PET-CT) and pathological biopsy, but these single-mode data provide limited perspective. The latest AI system can simultaneously analyze patients' pathological sections, medical imaging, and genomic data to generate unified diagnostic recommendations.
Taking lung cancer as an example, a study published in Nature Medicine in 2025 demonstrated a multimodal AI model that integrates CT imaging, histopathology, and genomic data. The model achieved an accuracy of AUC 0.94 in molecular subtype classification of non-small cell lung cancer, significantly better than the unimodal model (with an optimal AUC of 0.85). More importantly, the model is able to identify early molecular marker changes that traditional imaging cannot detect, advancing the early diagnostic window by 3-6 months.
3、 Clinical Decision Support: From Assistance to Collaboration
The role of multimodal AI in clinical decision support is evolving from an "auxiliary tool" to an "intelligent collaborative partner". The current typical applications include: drug genomics interaction prediction (recommending the best medication and dosage based on patient genomic data), treatment response prediction (predicting the probability of a patient's response to a specific treatment plan), and real-time monitoring and warning (combining wearable devices and electronic health record data to predict disease deterioration).
In the field of pharmacogenomics, AI systems have been able to analyze variations in key drug metabolism genes such as the CYP450 enzyme system, TPMT, and UGT1A1, providing personalized medication recommendations for patients with psychiatric disorders, tumors, and cardiovascular diseases. A prospective study by the Mayo Clinic in the United States in 2025 showed that AI assisted pharmacogenomic testing reduced the incidence of adverse drug reactions by about 35% while improving treatment efficacy.
4、 Challenges and Prospects
The large-scale application of multimodal AI in precision medicine still faces challenges in data integration, standardization, and privacy protection. The huge differences in data formats, collection standards, and storage methods among different hospitals and laboratories hinder the transferability of the model. Federated learning and privacy computing technologies are expected to achieve multi center model training without sharing raw data, but the maturity of the technology and regulatory framework still need to be further improved.
【 Reference source 】 Multimodal AI lung cancer research in Nature Medicine (2025); Prospective study on drug genomics at Mayo Clinic (2025); DeepMind AlphaFold Technology Report.